PH12018501731A1 - Positive allosteric modulators of the muscarinic acetylcholine receptor m1 - Google Patents
Positive allosteric modulators of the muscarinic acetylcholine receptor m1Info
- Publication number
- PH12018501731A1 PH12018501731A1 PH12018501731A PH12018501731A PH12018501731A1 PH 12018501731 A1 PH12018501731 A1 PH 12018501731A1 PH 12018501731 A PH12018501731 A PH 12018501731A PH 12018501731 A PH12018501731 A PH 12018501731A PH 12018501731 A1 PH12018501731 A1 PH 12018501731A1
- Authority
- PH
- Philippines
- Prior art keywords
- acetylcholine receptor
- positive allosteric
- allosteric modulators
- muscarinic acetylcholine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296012P | 2016-02-16 | 2016-02-16 | |
| US201662402438P | 2016-09-30 | 2016-09-30 | |
| PCT/US2017/018140 WO2017143041A1 (en) | 2016-02-16 | 2017-02-16 | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501731A1 true PH12018501731A1 (en) | 2019-06-17 |
Family
ID=59626207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501731A PH12018501731A1 (en) | 2016-02-16 | 2018-08-15 | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11111251B2 (OSRAM) |
| EP (1) | EP3416639B1 (OSRAM) |
| JP (1) | JP2019504901A (OSRAM) |
| KR (1) | KR20180110132A (OSRAM) |
| CN (1) | CN109069491A (OSRAM) |
| AU (1) | AU2017221404A1 (OSRAM) |
| BR (1) | BR112018016689A2 (OSRAM) |
| CA (1) | CA3014791A1 (OSRAM) |
| CL (1) | CL2018002335A1 (OSRAM) |
| EA (1) | EA201891854A1 (OSRAM) |
| IL (1) | IL261058A (OSRAM) |
| MA (1) | MA44253A (OSRAM) |
| MX (1) | MX385975B (OSRAM) |
| PH (1) | PH12018501731A1 (OSRAM) |
| WO (1) | WO2017143041A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102017786B1 (ko) | 2016-09-02 | 2019-09-03 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 포지티브 알로스테릭 조절제 |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| RS64722B1 (sr) * | 2017-06-20 | 2023-11-30 | Takeda Pharmaceuticals Co | Heterociklično jedinjenje i njegova upotreba kao pozitivnog alosteričkog modulatora holinergičkog muskarinskog m1 receptora |
| CN110709401B (zh) * | 2017-06-20 | 2023-06-13 | 武田药品工业株式会社 | 杂环化合物 |
| CN118063442A (zh) | 2017-10-20 | 2024-05-24 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| AU2018354969B2 (en) * | 2017-10-27 | 2020-09-17 | Suven Life Sciences Limited | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators |
| KR20200081424A (ko) | 2017-10-31 | 2020-07-07 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 길항제 |
| CN111788182B (zh) | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| WO2019241467A1 (en) * | 2018-06-13 | 2019-12-19 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US12162864B2 (en) | 2018-09-28 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| EP3858828A4 (en) | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| WO2020086864A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| WO2021067696A1 (en) | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4608079A (en) | 1983-08-02 | 1986-08-26 | American Cyanamid Company | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| ATE226208T1 (de) | 1999-03-09 | 2002-11-15 | Upjohn Co | 4-oxo-4,7-dihydro-thieno(2,3-b)pyridin-5- carboxamide als antivirale mittel |
| BR0110420A (pt) | 2000-04-28 | 2003-07-01 | Acadia Pharm Inc | Agonistas muscarìnicos |
| KR100614900B1 (ko) | 2001-10-02 | 2006-08-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물 |
| ME02421B (me) * | 2009-12-17 | 2016-09-20 | Merck Sharp & Dohme | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida |
| US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
| US8940765B2 (en) * | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| JP6271758B2 (ja) | 2014-01-22 | 2018-01-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フルオロ−ナフチル誘導体 |
| WO2015190564A1 (ja) * | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| KR102017786B1 (ko) | 2016-09-02 | 2019-09-03 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 포지티브 알로스테릭 조절제 |
-
2017
- 2017-02-16 AU AU2017221404A patent/AU2017221404A1/en not_active Abandoned
- 2017-02-16 KR KR1020187026643A patent/KR20180110132A/ko not_active Withdrawn
- 2017-02-16 MX MX2018009952A patent/MX385975B/es unknown
- 2017-02-16 EP EP17753822.0A patent/EP3416639B1/en active Active
- 2017-02-16 MA MA044253A patent/MA44253A/fr unknown
- 2017-02-16 US US15/998,899 patent/US11111251B2/en active Active
- 2017-02-16 EA EA201891854A patent/EA201891854A1/ru unknown
- 2017-02-16 CA CA3014791A patent/CA3014791A1/en active Pending
- 2017-02-16 WO PCT/US2017/018140 patent/WO2017143041A1/en not_active Ceased
- 2017-02-16 CN CN201780023438.3A patent/CN109069491A/zh active Pending
- 2017-02-16 BR BR112018016689A patent/BR112018016689A2/pt not_active IP Right Cessation
- 2017-02-16 JP JP2018561928A patent/JP2019504901A/ja active Pending
-
2018
- 2018-08-08 IL IL261058A patent/IL261058A/en unknown
- 2018-08-14 CL CL2018002335A patent/CL2018002335A1/es unknown
- 2018-08-15 PH PH12018501731A patent/PH12018501731A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018016689A2 (pt) | 2019-02-12 |
| WO2017143041A1 (en) | 2017-08-24 |
| IL261058A (en) | 2018-10-31 |
| CL2018002335A1 (es) | 2019-02-01 |
| US11111251B2 (en) | 2021-09-07 |
| MX385975B (es) | 2025-03-18 |
| AU2017221404A1 (en) | 2018-08-23 |
| EA201891854A1 (ru) | 2019-01-31 |
| EP3416639A1 (en) | 2018-12-26 |
| EP3416639B1 (en) | 2022-06-08 |
| KR20180110132A (ko) | 2018-10-08 |
| US20210230180A1 (en) | 2021-07-29 |
| CN109069491A (zh) | 2018-12-21 |
| CA3014791A1 (en) | 2017-08-24 |
| JP2019504901A (ja) | 2019-02-21 |
| EP3416639A4 (en) | 2019-07-03 |
| MA44253A (fr) | 2018-12-26 |
| MX2018009952A (es) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501731A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| GEP20207167B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| NZ737399A (en) | Ccr2 modulators | |
| CL2016002661A1 (es) | Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy. | |
| TN2019000149A1 (en) | Magl inhibitors | |
| CL2018002697A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos. | |
| PH12016500529A1 (en) | 4-azaindole derivatives | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| WO2019089676A8 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| BR112018016629A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| PH12022550838A1 (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| ZA202001321B (en) | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EP4335848A3 (en) | Dual magl and faah inhibitors | |
| EP3544961A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINE ACETYLCHOLINE RECEPTOR M4 | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SI3643718T1 (sl) | Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1 | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. | |
| BR112018007755A2 (pt) | moduladores alostéricos positivos do receptor muscarínico m4 de acetilcolina | |
| SI3586832T1 (sl) | Farmacevtski sestavek za zdravljenje zaprtja | |
| HK40002190A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| HK40039227A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| HK40038649A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| HK40015440A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| HK40015439A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |